Detalles de la búsqueda
1.
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials.
Pharm Stat
; 21(3): 671-690, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35102685
2.
REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study.
Retina
; 40(8): 1529-1539, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31385918
3.
RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study.
Retina
; 40(9): 1673-1685, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31764612
4.
Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study.
BMC Ophthalmol
; 20(1): 18, 2020 Jan 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31918685
6.
Generating the Right Evidence at the Right Time: Principles of a New Class of Flexible Augmented Clinical Trial Designs.
Clin Pharmacol Ther
; 113(5): 1132-1138, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36757107
7.
Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses.
Rheumatol Ther
; 9(2): 753-762, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35044647
8.
Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study.
Eye (Lond)
; 36(8): 1656-1661, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34326500
9.
The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.
Clin Ther
; 42(7): 1330-1360, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32622783
10.
Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study.
PLoS One
; 15(6): e0233595, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32492069
11.
Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study.
PLoS One
; 15(6): e0234739, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32555630
12.
Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study.
PLoS One
; 15(1): e0227557, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31961888
13.
Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis.
Ophthalmol Retina
; 2(11): 1087-1096, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31047547
14.
Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment.
Eur Endocrinol
; 13(2): 91-98, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29632615
15.
Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.
JAMA Ophthalmol
; 135(5): 424-431, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28384675
16.
Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials.
J Clin Epidemiol
; 56(4): 310-6, 2003 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-12767407
17.
Experimental designs for small randomised clinical trials: an algorithm for choice.
Orphanet J Rare Dis
; 8: 48, 2013 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-23531234
18.
Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation.
Am J Gastroenterol
; 101(11): 2558-69; quiz 2671, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17090282
19.
Testing and estimation in flexible group sequential designs with adaptive treatment selection.
Stat Med
; 24(24): 3697-714, 2005 Dec 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-16320264
20.
Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
Am J Gastroenterol
; 97(9): 2321-7, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12358251
Resultados
1 -
20
de 20
1
Próxima >
>>